| Nov 12 |
Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment
|
| Nov 6 |
Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules
|
| Nov 6 |
Gold Down Over 2%; CVS Health Shares Jump After Q3 Results
|
| Nov 6 |
Dow Jumps Over 1,200 Points; Donald Trump Wins White House
|
| Nov 6 |
Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates
|
| Oct 28 |
Sonnet stock tumbles 22% in wake of proposed offering filing
|
| Oct 10 |
Sonnet BioTherapeutics’ Strategic Deal to Develop DPN Treatment
|
| Oct 4 |
Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs
|
| Sep 30 |
Sonnet BioTherapeutics Announces Launch of CEO Corner Platform
|
| Sep 25 |
Sonnet BioTherapeutics to execute 1-for-8 reverse stock split
|
